In our study, murine models of primary and metastatic osteosarcoma were used to study the therapeutic efficacy of BEMPEG both as a monotherapy and in combination with inhibitors of the immune checkpoints PD‐1 and CTLA‐4. The gene discussed is CTLA4; the disease is osteosarcoma.